MCM
FTH

Moore Capital Management’s Faeth Therapeutics FTH Stock Holding History

Moore Capital Management’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,467
Closed -$519K – 852
2021
Q3 		$519K Sell
2,467
-3,908
-61% -$711K 0.01% 541
2021
Q2 		$1.24M Hold
6,375
– – 0.02% 507
2021
Q1 		$1.85M Buy
+6,375
New +$2.13M 0.02% 469

Other funds holding FTH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Moore Capital Management's FTH Position: Q4 2021 in Review

Moore Capital Management sold out of Faeth Therapeutics (FTH) in Q4 2021, closing a stake of 2,467 shares — an estimated $519K sold.

Moore Capital Management first reported a position in FTH in Q1 2021 and held it in 3 quarters. The position peaked at $1.85M in Q1 2021. 37 funds tracked by Wall St. Rank hold FTH as of Q4 2021.

  • Moore Capital Management reported no remaining Faeth Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Moore Capital Management sold 2,467 Faeth Therapeutics shares in Q4 2021, an estimated $519K.
  • Moore Capital Management first reported a position in Faeth Therapeutics in Q1 2021 and held it in 3 quarters.
  • Moore Capital Management's Faeth Therapeutics position peaked at $1.85M in Q1 2021.
  • 37 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q4 2021.

Based on Moore Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.